A Phase 3b, Multicenter, Prospective, Randomized, Double Blind, Placebocontrolled Study to Reduce Incidence of Pre-dialysis Hyperkalemia With Sodium Zirconium Cyclosilicate (DIALIZE)
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2018
At a glance
- Drugs Zirconium silicate (Primary)
- Indications Hyperkalaemia
- Focus Registrational; Therapeutic Use
- Acronyms DIALIZE
- Sponsors AstraZeneca
- 04 Jan 2018 Planned End Date changed from 13 Nov 2018 to 29 Nov 2018.
- 04 Jan 2018 Planned primary completion date changed from 13 Nov 2018 to 29 Nov 2018.
- 04 Jan 2018 Status changed from not yet recruiting to recruiting.